These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 33692503

  • 1. AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy.
    Kagiava A, Karaiskos C, Richter J, Tryfonos C, Jennings MJ, Heslegrave AJ, Sargiannidou I, Stavrou M, Zetterberg H, Reilly MM, Christodoulou C, Horvath R, Kleopa KA.
    Gene Ther; 2021 Nov; 28(10-11):659-675. PubMed ID: 33692503
    [Abstract] [Full Text] [Related]

  • 2. Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X.
    Kagiava A, Richter J, Tryfonos C, Karaiskos C, Heslegrave AJ, Sargiannidou I, Rossor AM, Zetterberg H, Reilly MM, Christodoulou C, Kleopa KA.
    Hum Mol Genet; 2019 Nov 01; 28(21):3528-3542. PubMed ID: 31411673
    [Abstract] [Full Text] [Related]

  • 3. Intraneural GJB1 gene delivery improves nerve pathology in a model of X-linked Charcot-Marie-Tooth disease.
    Sargiannidou I, Kagiava A, Bashiardes S, Richter J, Christodoulou C, Scherer SS, Kleopa KA.
    Ann Neurol; 2015 Aug 01; 78(2):303-16. PubMed ID: 26010264
    [Abstract] [Full Text] [Related]

  • 4. Intrathecal gene therapy in mouse models expressing CMT1X mutations.
    Kagiava A, Karaiskos C, Richter J, Tryfonos C, Lapathitis G, Sargiannidou I, Christodoulou C, Kleopa KA.
    Hum Mol Genet; 2018 Apr 15; 27(8):1460-1473. PubMed ID: 29462293
    [Abstract] [Full Text] [Related]

  • 5. Gene replacement therapy in two Golgi-retained CMT1X mutants before and after the onset of demyelinating neuropathy.
    Kagiava A, Karaiskos C, Lapathitis G, Heslegrave A, Sargiannidou I, Zetterberg H, Bosch A, Kleopa KA.
    Mol Ther Methods Clin Dev; 2023 Sep 14; 30():377-393. PubMed ID: 37645436
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Gene expression profiling studies in regenerating nerves in a mouse model for CMT1X: uninjured Cx32-knockout peripheral nerves display expression profile of injured wild type nerves.
    Freidin M, Asche-Godin S, Abrams CK.
    Exp Neurol; 2015 Jan 14; 263():339-49. PubMed ID: 25447941
    [Abstract] [Full Text] [Related]

  • 10. Molecular genetics of X-linked Charcot-Marie-Tooth disease.
    Kleopa KA, Scherer SS.
    Neuromolecular Med; 2006 Jan 14; 8(1-2):107-22. PubMed ID: 16775370
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Genetic epidemiology of Charcot-Marie-Tooth disease.
    Braathen GJ.
    Acta Neurol Scand Suppl; 2012 Jan 14; (193):iv-22. PubMed ID: 23106488
    [Abstract] [Full Text] [Related]

  • 14. How do mutations in GJB1 cause X-linked Charcot-Marie-Tooth disease?
    Kleopa KA, Abrams CK, Scherer SS.
    Brain Res; 2012 Dec 03; 1487():198-205. PubMed ID: 22771394
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. AAV1.NT-3 gene therapy for X-linked Charcot-Marie-Tooth neuropathy type 1.
    Ozes B, Myers M, Moss K, Mckinney J, Ridgley A, Chen L, Bai S, Abrams CK, Freidin MM, Mendell JR, Sahenk Z.
    Gene Ther; 2022 Apr 03; 29(3-4):127-137. PubMed ID: 33542455
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.